Biologicals and biosimilars economics

Selected publications on Health Economics and Health Technology Assessment on biologicals and biosimilars
Immun-mediated inflammatory diseases: rheumatoid diseases, inflammatory bowel disease (IBD), psoriasis
Onclogy
Department of Health Economics, Corvinus University of Budapest
Budapest HTA Consultancy
11 November 2019
Publications
László Gulácsi, Zsombor Zrubka, Valentin Brodszky, Fanni Rencz, Rieke Alten, Zoltán Szekanecz, and Márta Péntek, Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis, Advances in Therapy, 2019, Online First http://link.springer.com/article/ 10.1007/s12325-018-0869-8, IF (2017): 3,085 Scimago Q1
Zsombor Zrubka, László Gulácsi1, Valentin Brodszky, Fanni Rencz, Rieke Alten, Zoltán Szekanecz, and Márta Péntek, Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis, Expert Review of Pharmacoeconomics & Outcomes Research, DOI/MS ID: 10.1080/14737167.2019.1647104 /, IF (2018): 1,828 Scimago Q2 (open access)
Laszlo Gulacsi, Marta Pentek, Fanni Rencz, Valentin Brodszky, Petra Baji, Zsuzsanna Vegh, Krisztina B Gecse, Silvio Danese, Laurent Peyrin-Biroulet, Peter L. Lakatos, Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations, Current Medicinal Chemistry, Volume 26, Issue 2, 2019, DOI: 10.2174/0929867324666170406112304, IF (2017): 3,469 Scimago D1
Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United European Gastroenterol J. 2018 Mar;6(2):310-321. IF (2017): 3,477 Scimago Q2
Pentek M, Zrubka Z, Gulacsi L. The economic impact of biosimilars on chronic immune-mediated inflammatory diseases. Curr Pharm Des. 2017 Nov 29. doi: 10.2174/1381612824666171129193708 IF (2016): 2,611 Scimago: Q1.
Brodszky V, Bíró A, Szekanecz Z, Soós B, Baji P, Rencz F, Tóthfalusi L, Gulácsi L, Péntek M, Determinants of drug survival of biological therapies in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years or retrospective data, Clinico Economics and Outcomes Research, 2017:9 139–147. IF:- Scimago: Q1.
Gulácsi L, Brodszky V, Baji P, Rencz F, Péntek M. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Adv Ther. 2017 May;34(5):1128-1144.
Zsombor Zrubka, Economic aspects of biosimilar competition in Hungary, The treatment of rheumatic disorders, Society and Economy 39 (2017) 2, pp. 271–290, DOI: 10.1556/204.2017.39.2.6 IF: – ; Scimago: Q3.

Rencz F, Gulácsi L, Péntek M, Gecse KB, Dignass A, Halfvarson J, Gomollón F, Baji P, Peyrin-
Biroulet L, Lakatos PL, Brodszky V. Cost-utility of biological treatment sequences for luminal
Crohn’s disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):597-606.
doi:10.1080/14737167.2017.1322509
Márta Péntek, Péter L Lakatos, Talitha Oorsprong, László Gulácsi, Milena Pavlova, Wim
Groot, Fanni Rencz, Valentin Brodszky, Petra Baji and Crohn’s Disease Research Group,
Access to biologicals in Crohn’s disease in ten European countries, World Journal of
Gastroenterology. 2017, 23 volume 34 issue, 6294-6305. open access IF (2016): 3.365;
Scimago Q1.
Gulácsi L, Rencz F, Poór G, Szekanecz Z, Brodszky V, Baji P, Péntek M. Patients’ access to
biological therapy in chronic inflammatory conditions; per capita GDP does not explain the
intercountry differences. Ann Rheum Dis. 2016 May;75(5):942-3.

 

Petra Baji, László Gulácsi, Petra A. Golovics, Barbara D. Lovász, Márta Péntek, Valentin
Brodszky, Fanni Rencz, Péter L. Lakatos, Perceived risks contra benefits of using biosimilar
drugs in ulcerative colitis; discrete choice experiment among gastroenterologists, Value in
Health Regional Issues, 2016. Scimago Q2
Thomas Dörner, Vibeke Strand, Paul Cornes, João Gonçalves, László Gulácsi, Jonathan Kay,
Tore K Kvien, Josef Smolen, Yoshiya Tanaka, Gerd R. Burmester, The changing landscape of
biosimilars in rheumatology, Annals of the Rheumatic Diseases the EULAR Journal, 2016,
75(6):974-82. IF (2015): 12.384. Scimago Q1
Rencz F, Kemény L, Gajdácsi JZ, Owczarek W, Arenberger P, Tiplica GS, Stanimirović A,
Niewada M, Petrova G, Marinov LT, Kazandhieva J, Péntek M, Brodszky V, Gulácsi L. Use
of biologics for psoriasis in Central and Eastern European countries. J Eur Acad Dermatol
Venereol. 2015 Nov;29(11):2222-30. doi: 10.1111/jdv.13222
Gulácsi L, Brodszky V, Baji P, Kim H, Kim SY, Cho YY, Péntek M. Biosimilars for the
management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol.
2015;11 Suppl 1:S43-52.
Valentin Brodszky, Fanni Rencz, Márta Péntek, Petra Baji, Péter L. Lakatos, László Gulácsi.
A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech
Republic, Hungary, Poland, Romania and Slovakia. Expert Rev Pharmacoecon Outcomes Res.
2015 Jul 10:1-7. IF (2014): 1,669. Scimago Q2
Petra Baji, László Gulácsi, Barbara D. Lovász, Petra A. Golovics, Valentin Brodszky, Márta
Péntek, Fanni Rencz, Péter Lakatos. Treatment preferences of originator versus biosimilar
drugs in Crohn’s disease; discrete choice experiment among gastroenterologists. Scandinavian
Journal of Gastroenterology. 2015 June 10: 1-6 IF (2014): 2,361. Scimago Q2
Fanni Rencz, Márta Péntek, Martin Bortlik, Edyta Zagorowicz, Tibor Hlavaty, Andrzej
Śliwczyński, Mihai M Diculescu, Limas Kupcinskas, Krisztina B Gecse, László Gulácsi, Peter
L Lakatos, Biological therapy in inflammatory bowel diseases: access in Central and Eastern
Europe, World J Gastroenterol 2015 February 14; 21(6): 1728-1737. IF (2014): 2,369. Scimago Q1

Brodszky V, Gulacsi L, Balogh O, Baji P, Rencz F, Péntek M. Budget Impact Analysis Of
Biosimilar Infliximab For The Treatment Of Crohn’s Disease In Six Central Eastern European
Countries. Value Health. 2014 Nov;17(7):A364. doi: 10.1016/j.jval.2014.08.805
Mandel MD, Bálint A, Lovász BD, Gulácsi L, Strbák B, Golovics PA, Farkas K, Kürti Z,
Szilágyi BK, Mohás A, Molnár T, Lakatos PL. Work disability and productivity loss in
patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health
Econ. 2014 May;15 Suppl 1:S121-8. doi: 10.1007/s10198-014-0603-7
Balogh O, Brodszky V, Gulácsi L, Herédi E, Herszényi K, Jókai H, Kárpáti S, Baji P,
Remenyik É, Szegedi A, Holló P. Cost-of-illness in patients with moderate to severe
psoriasis: a cross-sectional survey in Hungarian dermatological centres. Eur J Health Econ.
2014 May;15 Suppl 1:S101-9. doi: 10.1007/s10198-014-0599-z
Péntek M, Gulácsi L, Rojkovich B, Brodszky V, van Exel J, Brouwer WB. Subjective health
expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and
rheumatologists. Eur J Health Econ. 2014 May;15 Suppl 1:S83-92. doi: 10.1007/s10198-014-
0597-1
Baji P, Péntek M, Czirják L, Szekanecz Z, Nagy G, Gulácsi L, Brodszky V. Efficacy and
safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a
mixed treatment comparison. Eur J Health Econ. 2014 May;15 Suppl 1:S53-64. doi:
10.1007/s10198-014-0594-4
Baji P, Péntek M, Szántó S, Géher P, Gulácsi L, Balogh O, Brodszky V. Comparative
efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing
spondylitis: systematic literature review and meta-analysis. Eur J Health Econ. 2014 May;15
Suppl 1:S45-52. doi: 10.1007/s10198-014-0593-5. Epub 2014 May 16
Péntek M, Poór G, Wiland P, Olejárová M, Brzosko M, Codreanu C, Brodszky N, Gulácsi L.
Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern
European countries. Eur J Health Econ. 2014 May;15 Suppl 1:S35-43. doi: 10.1007/s10198-
014-0592-6
Gulácsi L, Rencz F, Péntek M, Brodszky V, Lopert R, Hevér NV, Baji P. Transferability of
results of cost utility analyses for biologicals in inflammatory conditions for Central and
Eastern European countries. Eur J Health Econ. 2014 May;15 Suppl 1:S27-34. doi:
10.1007/s10198-014-0591-7
Gulácsi L. Biological and biosimilar therapies in inflammatory conditions: challenges for the
Central and Eastern European countries. Eur J Health Econ. 2014 May;15 Suppl 1:S1-4. doi:
10.1007/s10198-014-0588-2
Koncz T, Pentek M, Brodszky V, Ersek K, Orlewska E, Gulacsi L. Adherence to
biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther. 2010
Sep;10(9):1367-78. doi: 10.1517/14712598.2010.510508
Gulácsi L. Future challenges for health economics and health technology
assessment of biological drugs. Eur J Health Econ. 2010 Jun;11(3):235-8. doi:
10.1007/s10198-010-0246-2

Brodszky V, Orlewska E, Pentek M, Karpati K, Skoupa J, Gulacsi L. Challenges
in economic evaluation of new drugs: experience with rituximab in Hungary. Med
Sci Monit. 2010 Jan;16(1):SR1-5
Brodszky V, Czirják L, Géher P, Hodinka L, Kárpáti K, Péntek M, Poór G, Szekanecz Z,
Gulácsi L. [Rituximab in patients with rheumatoid arthritis: systematic review]. Orv Hetil.
2007 Oct 7;148(40):1883-93
Koó E, Brodszky V, Péntek M, Ujfalussy I, Nagy MB, Gulácsi L. [The role of biological
agents in the treatment of psoriatic arthritis, literature review]. Orv Hetil. 2006 Oct
15;147(41):1963-70
Géher P, Nagy MB, Péntek M, Tóth E, Brodszky V, Gulácsi L. [The role of biologic agents in
the therapy of ankylosing spondylitis]. Orv Hetil. 2006 Jul 2;147(26):1203-13
Kemény L, Brodszky V, Kárpáti K, Gulácsi L. [The role of biological drugs in the treatment
of psoriasis, results from 9 randomized placebo-controlled trials]. Orv Hetil. 2006 May
28;147(21):981-90